Experimental coronavirus treatment remdesivir flops in China trial: reports [FOX News]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: FOX News
closeVideoUS doctors race against time to develop coronavirus cureMany top researchers are skipping peer-review journals and clinical protocols to speed up COVID-19 drugs and therapies.Get all the latest news on coronavirus and more delivered daily to your inbox.Sign up hereThe experimentalremdesivirCiting draft documents published accidentally by the Health Organization, the Financial TimesreportsThe Chinese trial did not improve patients’ condition or remove the pathogen’s presence in their bloodstream, according to the FT. The trial compiled data from 237 patients, it said, 158 of whom received the drug. Their progress was compared to the remaining 79 patients in the study. Significant side effects were also reportedly seen in some patients, which meant that 18 were taken off the drug.Health news site STAT alsoREMDESIVIR: WHAT TO KNOW ABOUT POTENTIAL CORONAVIRUS TREATMENTIn a statement obtained by Fox News, a Gilead Sciences spokesperson said the WHO documents "included inappropri
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.MarketBeat
- Hopping Mad Over Drug Company Product Hopping [Forbes]Forbes
- Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/15/26 - Form 144
- GILD's page on the SEC website